Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.
Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the world; about one million of those living in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. Current therapies primarily focus on modulating the immune system to reduce relapses but do not address the underlying neurodegeneration or promote repair. Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Lucid-MS is designed to promote remyelination and protect neurons, potentially halting or reversing disease progression. Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital, which uses advanced MRI techniques to measure myelin repair in patients.
In addition to its MS program, Quantum BioPharma has developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. The supplement is designed to accelerate the breakdown of alcohol and its toxic byproducts, potentially reducing impairment and the negative aftereffects of alcohol consumption. This product addresses a widespread issue affecting millions who consume alcohol, offering a novel approach to mitigating its acute neurological and physiological impacts.
The company’s dual focus on chronic neurodegenerative disease and acute alcohol-related brain dysfunction highlights its commitment to addressing neurological conditions across the spectrum. By targeting both remyelination in MS and alcohol metabolism, Quantum BioPharma aims to provide solutions where current options are limited. For more information on the company and its pipeline, visit its newsroom at https://ibn.fm/QNTM.
